- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05217810
24-недельное проспективное, открытое, многоцентровое, одногрупповое исследование rPMS в реальных условиях для Atectura®
24-недельное проспективное, открытое, многоцентровое, одногрупповое исследование пострегистрационного надзора (rPMS) в реальных условиях (обязательно согласно местным правилам HA) для Atectura® (QMF149 150/80 мкг o.d., QMF149 150/ 160 мкг 1 раз в сутки и QMF149 150/320 мкг 1 раз в сутки через Бризхайлер)
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
Обзор исследования
Статус
Условия
Подробное описание
The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
-
Busan, Южная Корея, 48108
- Novartis Investigative Site
-
Gyeongsangnam Do, Южная Корея, 51353
- Novartis Investigative Site
-
Jeju City, Южная Корея, 63241
- Novartis Investigative Site
-
Seoul, Южная Корея, 05505
- Novartis Investigative Site
-
Seoul, Южная Корея, 04763
- Novartis Investigative Site
-
Seoul, Южная Корея, 06273
- Novartis Investigative Site
-
Seoul, Южная Корея, 137 707
- Novartis Investigative Site
-
Taegu, Южная Корея, 41944
- Novartis Investigative Site
-
Ulsan, Южная Корея, 44033
- Novartis Investigative Site
-
-
Dalseo gu
-
Daegu, Dalseo gu, Южная Корея, 42602
- Novartis Investigative Site
-
-
Gangneung si
-
Kangwon Do, Gangneung si, Южная Корея, 210 711
- Novartis Investigative Site
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Южная Корея, 26426
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Южная Корея, 10380
- Novartis Investigative Site
-
Guri-si, Gyeonggi-do, Южная Корея, 11923
- Novartis Investigative Site
-
-
Gyeongsangnam-do
-
Jinju, Gyeongsangnam-do, Южная Корея, 52727
- Novartis Investigative Site
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Южная Корея, 54907
- Novartis Investigative Site
-
-
Jeonlabuk Do
-
Iksan Si, Jeonlabuk Do, Южная Корея, 54538
- Novartis Investigative Site
-
-
Korea
-
Daejeon, Korea, Южная Корея, 35015
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.
Описание
Inclusion Criteria:
- Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
- Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)
Exclusion Criteria:
- Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
- Patients participating in other interventional clinical trials
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Atectura inhalation capsule (150/80ug)
Indacaterol acetate/Mometasone furoate; 150/80ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/160ug)
Indacaterol acetate/Mometasone furoate; 150/160ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/320ug)
Indacaterol acetate/Mometasone furoate; 150/320ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of adverse events and serious adverse events
Временное ограничение: 24 weeks
|
Incidence of AE and SAE will be collected |
24 weeks
|
|
Incidence of unexpected adverse events and unexpected serious adverse events
Временное ограничение: 24 weeks
|
Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label |
24 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
change from baseline in trough FEV1
Временное ограничение: Baseline, week 12
|
Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. |
Baseline, week 12
|
|
change from baseline in ACT score
Временное ограничение: Baseline, week 12
|
The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement. |
Baseline, week 12
|
|
Effective rate and ineffective rate by investigator assessment
Временное ограничение: week 12
|
Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment |
week 12
|
|
Baseline characteristics of patients showing adverse events/adverse drug reactions
Временное ограничение: 24 weeks
|
The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
24 weeks
|
|
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Временное ограничение: 12 weeks
|
Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations |
12 weeks
|
|
Baseline characteristics of patients in relation to the investigator assessment
Временное ограничение: 12 weeks
|
Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
12 weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CQMF149EKR01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .